NASDAQ:WVE - Wave Life Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $37.60 +1.07 (+2.93 %) (As of 02/15/2019 04:00 PM ET)Previous Close$37.60Today's Range$36.66 - $37.6152-Week Range$32.25 - $56.00Volume197,248 shsAverage Volume406,947 shsMarket Capitalization$1.11 billionP/E Ratio-9.77Dividend YieldN/ABeta0.82 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore. Receive WVE News and Ratings via Email Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:WVE Previous Symbol CUSIPN/A Webwww.wavelifesciences.com Phone65-6236-3388Debt Debt-to-Equity Ratio0.08 Current Ratio1.85 Quick Ratio1.85Price-To-Earnings Trailing P/E Ratio-9.77 Forward P/E Ratio-7.52 P/E GrowthN/A Sales & Book Value Annual Sales$3.70 million Price / Sales299.42 Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book7.48Profitability EPS (Most Recent Fiscal Year)($3.85) Net Income$-102,030,000.00 Net Margins-1,114.49% Return on Equity-112.13% Return on Assets-55.01%Miscellaneous Employees168 Outstanding Shares29,464,000Market Cap$1.11 billion OptionableOptionable Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions What is Wave Life Sciences' stock symbol? Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE." How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd (NASDAQ:WVE) announced its quarterly earnings data on Friday, November, 9th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.26) by $0.02. The firm had revenue of $4.49 million for the quarter, compared to analyst estimates of $5.36 million. Wave Life Sciences had a negative net margin of 1,114.49% and a negative return on equity of 112.13%. View Wave Life Sciences' Earnings History. When is Wave Life Sciences' next earnings date? Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Wave Life Sciences. What price target have analysts set for WVE? 5 analysts have issued twelve-month target prices for Wave Life Sciences' shares. Their forecasts range from $49.00 to $65.00. On average, they anticipate Wave Life Sciences' share price to reach $58.20 in the next twelve months. This suggests a possible upside of 54.8% from the stock's current price. View Analyst Price Targets for Wave Life Sciences. What is the consensus analysts' recommendation for Wave Life Sciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences. What are Wall Street analysts saying about Wave Life Sciences stock? Here are some recent quotes from research analysts about Wave Life Sciences stock: 1. According to Zacks Investment Research, "WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. " (1/26/2019) 2. HC Wainwright analysts commented, "We value $49/share based on a risk-adjusted, sum-of-parts DCF analysis: beta of 0.69, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 6.6%, and tax rate of 15% beginning in FY 2027. We value $3/share, respectively, which together account for roughly 90% of our target with the remainder derived from FTD and ALS expected to enter the clinic during 2019. Risks to our target include: commercial, reimbursement, regulatory, along with clinical and manufacturing." (12/10/2018) Has Wave Life Sciences been receiving favorable news coverage? News stories about WVE stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Wave Life Sciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Wave Life Sciences' key competitors? Some companies that are related to Wave Life Sciences include TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Evotec (EVTCY), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT) and Ligand Pharmaceuticals (LGND). Who are Wave Life Sciences' key executives? Wave Life Sciences' management team includes the folowing people: Dr. Paul B. Bolno, Pres, CEO & Director (Age 45)Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 41)Dr. Chandra Vargeese, Sr. VP of Drug Discovery (Age 58)Mr. Keith Regnante, Chief Financial Officer (Age 49)Mr. Kyle B. Moran, Sr. VP of Operations & Bus. Analytics (Age 48) Who are Wave Life Sciences' major shareholders? Wave Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.27%), BB Biotech AG (4.97%), Northern Trust Corp (0.77%), Geode Capital Management LLC (0.66%), D. E. Shaw & Co. Inc. (0.43%) and WS Management Lllp (0.27%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences. Which major investors are selling Wave Life Sciences stock? WVE stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Millennium Management LLC, WS Management Lllp, Bailard Inc., New York State Common Retirement Fund, Northern Trust Corp and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences. Which major investors are buying Wave Life Sciences stock? WVE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., BB Biotech AG, D. E. Shaw & Co. Inc., Geode Capital Management LLC, Wexford Capital LP, Bank of America Corp DE, Rhumbline Advisers and Virtus ETF Advisers LLC. View Insider Buying and Selling for Wave Life Sciences. How do I buy shares of Wave Life Sciences? Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Wave Life Sciences' stock price today? One share of WVE stock can currently be purchased for approximately $37.60. How big of a company is Wave Life Sciences? Wave Life Sciences has a market capitalization of $1.11 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe. What is Wave Life Sciences' official website? The official website for Wave Life Sciences is http://www.wavelifesciences.com. How can I contact Wave Life Sciences? Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected] MarketBeat Community Rating for Wave Life Sciences (NASDAQ WVE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 237 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 426MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What are convertible shares?